SI-BONE's iFuse® system for sacroiliac joint fusion will be added to the List of Refundable Products and Services in France (Liste des Produits et Prestations Remboursables - LPPR), thus gaining French National Healthcare System coverage. This reimbursement is exclusive to the iFuse implant, starts next month and is effective for five years.

A national commission recommends coverage for second-line treatment of sacroiliac joint dysfunction caused by SI joint disruption or degenerative sacroiliitis in patients who fail to respond to conservative treatment. 

Source: SI-BONE, Inc.